Enliven Therapeutics, Inc (ELVN) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
March 13, 2025 4:05 PM EDTUpdated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025
Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027
BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics,... More
